STOCK TITAN

[Form 4] IBEX Limited Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

IBEX Ltd (IBEX) Form 4 filing discloses two open-market sales by Chief Executive Officer and Director Robert Thomas Dechant on 2 and 3 July 2025. The transactions involved a total of 5,000 common shares sold at $30.00 per share, producing proceeds of roughly $150,000. Following the dispositions, Dechant’s direct ownership declined from 198,633 to 193,633 shares, a reduction of about 2.5% of his previously held stake. No derivative security activity was reported, and the filing was submitted individually on 3 July 2025.

The modest size of the sale relative to Dechant’s remaining holdings suggests routine portfolio management rather than a wholesale change in insider sentiment. Nonetheless, any CEO sale can attract investor attention, particularly when not explicitly tied to a pre-arranged 10b5-1 trading plan (the form does not indicate such a plan was in place).

IBEX Ltd (IBEX) Comunicazione Form 4 rivela due vendite sul mercato aperto da parte dell'Amministratore Delegato e Direttore Robert Thomas Dechant effettuate il 2 e 3 luglio 2025. Le transazioni hanno coinvolto un totale di 5.000 azioni ordinarie vendute a $30,00 per azione, generando proventi di circa $150.000. Dopo queste operazioni, la proprietà diretta di Dechant è scesa da 198.633 a 193.633 azioni, una riduzione di circa il 2,5% della sua partecipazione precedente. Non sono state segnalate attività su strumenti derivati e la comunicazione è stata presentata individualmente il 3 luglio 2025.

La dimensione contenuta della vendita rispetto alle partecipazioni residue di Dechant suggerisce una gestione ordinaria del portafoglio piuttosto che un cambiamento radicale nel sentimento interno. Tuttavia, qualsiasi vendita da parte del CEO può attirare l'attenzione degli investitori, specialmente se non collegata esplicitamente a un piano di trading predefinito 10b5-1 (il modulo non indica la presenza di tale piano).

IBEX Ltd (IBEX) Presentación del Formulario 4 revela dos ventas en el mercado abierto realizadas por el Director Ejecutivo y Director Robert Thomas Dechant los días 2 y 3 de julio de 2025. Las transacciones involucraron un total de 5,000 acciones ordinarias vendidas a $30.00 por acción, generando ingresos aproximados de $150,000. Tras estas disposiciones, la propiedad directa de Dechant disminuyó de 198,633 a 193,633 acciones, una reducción de alrededor del 2.5% de su participación previa. No se reportó actividad en valores derivados y la presentación se realizó de forma individual el 3 de julio de 2025.

El tamaño modesto de la venta en relación con las participaciones restantes de Dechant sugiere una gestión rutinaria de cartera más que un cambio radical en el sentimiento interno. No obstante, cualquier venta por parte del CEO puede atraer la atención de los inversores, especialmente cuando no está explícitamente vinculada a un plan de negociación 10b5-1 preestablecido (el formulario no indica que dicho plan estuviera en vigor).

IBEX Ltd (IBEX) Form 4 제출은 최고경영자 겸 이사인 로버트 토마스 디샨트가 2025년 7월 2일과 3일에 공개 시장에서 주식을 매도한 사실을 공개합니다. 이 거래는 총 5,000주 보통주를 주당 $30.00에 매도하여 약 $150,000의 수익을 창출했습니다. 매도 후 디샨트의 직접 소유 주식은 198,633주에서 193,633주로 줄어들어 이전 보유 지분의 약 2.5% 감소를 나타냅니다. 파생상품 거래 내역은 보고되지 않았으며, 제출은 2025년 7월 3일 개인 자격으로 이루어졌습니다.

디샨트의 남은 보유 주식에 비해 매도 규모가 크지 않은 점은 내부자의 심리 변화보다는 일상적인 포트폴리오 관리로 보입니다. 그럼에도 불구하고, CEO의 주식 매도는 사전 설정된 10b5-1 거래 계획과 명확히 연계되지 않은 경우 투자자들의 관심을 끌 수 있습니다(서류에는 해당 계획이 존재한다는 언급이 없습니다).

IBEX Ltd (IBEX) Déclaration Formulaire 4 révèle deux ventes sur le marché libre effectuées par le Directeur Général et Administrateur Robert Thomas Dechant les 2 et 3 juillet 2025. Les transactions ont porté sur un total de 5 000 actions ordinaires vendues à 30,00 $ par action, générant des recettes d'environ 150 000 $. Après ces cessions, la détention directe de Dechant est passée de 198 633 à 193 633 actions, soit une réduction d'environ 2,5 % de sa participation antérieure. Aucune activité sur des instruments dérivés n'a été signalée, et la déclaration a été soumise individuellement le 3 juillet 2025.

La taille modeste de la vente par rapport aux avoirs restants de Dechant suggère une gestion courante du portefeuille plutôt qu'un changement radical du sentiment interne. Néanmoins, toute vente par un PDG peut attirer l'attention des investisseurs, surtout si elle n'est pas explicitement liée à un plan de trading 10b5-1 préétabli (le formulaire n'indique pas qu'un tel plan était en place).

IBEX Ltd (IBEX) Form 4 Einreichung offenbart zwei Verkäufe am offenen Markt durch den Geschäftsführer und Direktor Robert Thomas Dechant am 2. und 3. Juli 2025. Die Transaktionen betrafen insgesamt 5.000 Stammaktien, die zu je $30,00 verkauft wurden, was Erlöse von etwa $150.000 einbrachte. Nach diesen Veräußerungen sank Dechants Direktbesitz von 198.633 auf 193.633 Aktien, eine Reduzierung um etwa 2,5 % seines zuvor gehaltenen Anteils. Es wurde keine Aktivität mit Derivaten gemeldet, und die Einreichung erfolgte einzeln am 3. Juli 2025.

Die vergleichsweise geringe Verkaufsmenge im Verhältnis zu Dechants verbleibenden Anteilen deutet eher auf eine routinemäßige Portfolioverwaltung als auf eine grundlegende Änderung der Insider-Stimmung hin. Dennoch kann jeder Verkauf eines CEO die Aufmerksamkeit der Investoren auf sich ziehen, insbesondere wenn er nicht ausdrücklich an einen vorab festgelegten 10b5-1-Handelsplan gebunden ist (das Formular weist auf einen solchen Plan nicht hin).

Positive
  • CEO retains a substantial 193,633-share position, indicating continued equity alignment with shareholders.
  • Prompt disclosure via Form 4 enhances transparency around insider transactions.
Negative
  • Insider sale of 5,000 shares (~2.5% of holdings) may raise modest concern about near-term confidence.
  • No 10b5-1 plan indicated, suggesting discretionary timing of the sales.

Insights

TL;DR: CEO sells 5,000 shares (≈2.5%)—small, likely immaterial, but worth monitoring.

The transaction totals about $150k and leaves Robert Dechant with more than 193k shares, maintaining significant alignment with shareholders. The absence of any 10b5-1 notation means the sales were discretionary, yet the limited size relative to his stake and IBEX’s public float points to low materiality. For most investors, this is a neutral governance datapoint rather than a valuation catalyst, though persistent insider selling could signal growing caution if it continues.

IBEX Ltd (IBEX) Comunicazione Form 4 rivela due vendite sul mercato aperto da parte dell'Amministratore Delegato e Direttore Robert Thomas Dechant effettuate il 2 e 3 luglio 2025. Le transazioni hanno coinvolto un totale di 5.000 azioni ordinarie vendute a $30,00 per azione, generando proventi di circa $150.000. Dopo queste operazioni, la proprietà diretta di Dechant è scesa da 198.633 a 193.633 azioni, una riduzione di circa il 2,5% della sua partecipazione precedente. Non sono state segnalate attività su strumenti derivati e la comunicazione è stata presentata individualmente il 3 luglio 2025.

La dimensione contenuta della vendita rispetto alle partecipazioni residue di Dechant suggerisce una gestione ordinaria del portafoglio piuttosto che un cambiamento radicale nel sentimento interno. Tuttavia, qualsiasi vendita da parte del CEO può attirare l'attenzione degli investitori, specialmente se non collegata esplicitamente a un piano di trading predefinito 10b5-1 (il modulo non indica la presenza di tale piano).

IBEX Ltd (IBEX) Presentación del Formulario 4 revela dos ventas en el mercado abierto realizadas por el Director Ejecutivo y Director Robert Thomas Dechant los días 2 y 3 de julio de 2025. Las transacciones involucraron un total de 5,000 acciones ordinarias vendidas a $30.00 por acción, generando ingresos aproximados de $150,000. Tras estas disposiciones, la propiedad directa de Dechant disminuyó de 198,633 a 193,633 acciones, una reducción de alrededor del 2.5% de su participación previa. No se reportó actividad en valores derivados y la presentación se realizó de forma individual el 3 de julio de 2025.

El tamaño modesto de la venta en relación con las participaciones restantes de Dechant sugiere una gestión rutinaria de cartera más que un cambio radical en el sentimiento interno. No obstante, cualquier venta por parte del CEO puede atraer la atención de los inversores, especialmente cuando no está explícitamente vinculada a un plan de negociación 10b5-1 preestablecido (el formulario no indica que dicho plan estuviera en vigor).

IBEX Ltd (IBEX) Form 4 제출은 최고경영자 겸 이사인 로버트 토마스 디샨트가 2025년 7월 2일과 3일에 공개 시장에서 주식을 매도한 사실을 공개합니다. 이 거래는 총 5,000주 보통주를 주당 $30.00에 매도하여 약 $150,000의 수익을 창출했습니다. 매도 후 디샨트의 직접 소유 주식은 198,633주에서 193,633주로 줄어들어 이전 보유 지분의 약 2.5% 감소를 나타냅니다. 파생상품 거래 내역은 보고되지 않았으며, 제출은 2025년 7월 3일 개인 자격으로 이루어졌습니다.

디샨트의 남은 보유 주식에 비해 매도 규모가 크지 않은 점은 내부자의 심리 변화보다는 일상적인 포트폴리오 관리로 보입니다. 그럼에도 불구하고, CEO의 주식 매도는 사전 설정된 10b5-1 거래 계획과 명확히 연계되지 않은 경우 투자자들의 관심을 끌 수 있습니다(서류에는 해당 계획이 존재한다는 언급이 없습니다).

IBEX Ltd (IBEX) Déclaration Formulaire 4 révèle deux ventes sur le marché libre effectuées par le Directeur Général et Administrateur Robert Thomas Dechant les 2 et 3 juillet 2025. Les transactions ont porté sur un total de 5 000 actions ordinaires vendues à 30,00 $ par action, générant des recettes d'environ 150 000 $. Après ces cessions, la détention directe de Dechant est passée de 198 633 à 193 633 actions, soit une réduction d'environ 2,5 % de sa participation antérieure. Aucune activité sur des instruments dérivés n'a été signalée, et la déclaration a été soumise individuellement le 3 juillet 2025.

La taille modeste de la vente par rapport aux avoirs restants de Dechant suggère une gestion courante du portefeuille plutôt qu'un changement radical du sentiment interne. Néanmoins, toute vente par un PDG peut attirer l'attention des investisseurs, surtout si elle n'est pas explicitement liée à un plan de trading 10b5-1 préétabli (le formulaire n'indique pas qu'un tel plan était en place).

IBEX Ltd (IBEX) Form 4 Einreichung offenbart zwei Verkäufe am offenen Markt durch den Geschäftsführer und Direktor Robert Thomas Dechant am 2. und 3. Juli 2025. Die Transaktionen betrafen insgesamt 5.000 Stammaktien, die zu je $30,00 verkauft wurden, was Erlöse von etwa $150.000 einbrachte. Nach diesen Veräußerungen sank Dechants Direktbesitz von 198.633 auf 193.633 Aktien, eine Reduzierung um etwa 2,5 % seines zuvor gehaltenen Anteils. Es wurde keine Aktivität mit Derivaten gemeldet, und die Einreichung erfolgte einzeln am 3. Juli 2025.

Die vergleichsweise geringe Verkaufsmenge im Verhältnis zu Dechants verbleibenden Anteilen deutet eher auf eine routinemäßige Portfolioverwaltung als auf eine grundlegende Änderung der Insider-Stimmung hin. Dennoch kann jeder Verkauf eines CEO die Aufmerksamkeit der Investoren auf sich ziehen, insbesondere wenn er nicht ausdrücklich an einen vorab festgelegten 10b5-1-Handelsplan gebunden ist (das Formular weist auf einen solchen Plan nicht hin).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dechant Robert Thomas

(Last) (First) (Middle)
C/O IBEX LIMITED
1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)
WASHINGTON DC 20006

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 07/02/2025 S 624 D $30 198,009 D
Common Shares 07/03/2025 S 4,376 D $30 193,633 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Lisa Lenstrohm, Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IBEX shares did CEO Robert Dechant sell?

He sold a total of 5,000 common shares (624 on 07/02/2025 and 4,376 on 07/03/2025).

At what price were the IBEX shares sold?

Both transactions were reported at $30.00 per share.

How many IBEX shares does the CEO still own after the sale?

After the reported sales, Dechant directly holds 193,633 common shares.

Was the sale made under a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the transactions were executed under a 10b5-1 plan.

Does this insider sale significantly impact IBEX’s outlook?

Given the sale represents roughly 2.5% of the CEO’s holdings, it is generally viewed as low-impact for the company’s fundamentals.
Ibex Ltd

NASDAQ:IBEX

IBEX Rankings

IBEX Latest News

IBEX Latest SEC Filings

IBEX Stock Data

385.39M
11.58M
13.91%
80.19%
0.85%
Information Technology Services
Services-computer Processing & Data Preparation
Link
United States
WASHINGTON